World-First Registered Indication for Chronic Breathlessness - 19 February 2019

Australian Therapeutic Goods Administration (TGA) has approved a world-first indication for a pharmacological agent for the symptomatic reduction of chronic breathlessness.

More than 70,000 Australians who suffer from chronic breathlessness willnow have access to life-changing medication to manage their symptoms. In a world first, Mayne Pharma International Pty Ltd announced the listing of Kapanol® low dose sustained-release morphine on the Australian Register of Therapeutic Good (ARTG) for the symptomatic reduction of chronic breathlessness.

Many of the people set to benefit have chronic lung disease, are often housebound and limited in their day-to-day activities. 

This once-a-day capsule offers a new way to reduce their debilitating symptoms. The research underpinning this listing was conducted in Australia by researchers and clinicians across the country. The Australian national Palliative Care Clinical Studies Collaborative, formerly at Flinders University and now based at University of Technology Sydney, has built on work started more than 20 years ago to study the effectiveness and safety of regular, low dose extended-release morphine for the symptomatic reduction of chronic breathlessness. The work, led by the principal investigator of the Collaborative, Professor David Currow, has engaged clinician-researchers in every mainland state.